texas oncology more breakthroughs. more victories

Share:

 
 

East Texas Clinical Trials

Texas Oncology cancer centers in east Texas participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the east Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the east Texas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the east Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the east Texas area and talk to you doctor to determine which clinical trial is right for you.

Biliary Cancer

Title: PI/II Cholangiocarcinoma CX-4945 w Gem View

Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PI/II Cholangiocarcinoma CX-4945 w Gem View

Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)

Indication: Biliary Cancer

Location: Texas Oncology-Canton

Phase: II

Bladder Cancer

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Brain Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Canton

Phase: I

Breast Cancer

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph2 SC Pertuz+Trastuz HER2+ BC View

Description: A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2- POSITIVE EARLY BREAST CANCER (MO40628)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 SC Pertuz+Trastuz HER2+ BC View

Description: A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2- POSITIVE EARLY BREAST CANCER (MO40628)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Cervical Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: II

Colon Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I

Endometrial Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Epithelial Carcinomas

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Longview Cancer Center

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Tyler

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Canton

Esophageal Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: II

Fallopian Tube Cancer

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: III

Gastric Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II

GI Stromal Tumor (GIST)

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Canton

Phase: III

Head and Neck Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: II

Hematologic

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Canton

Phase: III

Leukemia

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: I

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Liver Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/2 AGEN1884 Adv Refractory cancer View

Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 AGEN1884 Adv Refractory cancer View

Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I/II

Lung Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III/IV

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II/III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Lymphomas

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b/2 R/R FL, R/R DLBCL View

Description: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 R/R FL, R/R DLBCL View

Description: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Melanoma

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I

Myelodysplastic Syndrome

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: I

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: III

Myelofibrosis

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: I

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: II

Myelomas

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: I

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: IV

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: I/II

Ovarian Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Pancreatic Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: III

Peritoneal Cancer

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: III

Prostate Cancer

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: I

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Rectal Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Canton

Phase: II

Renal Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I

Solid Tumors

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Testicular Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: II

Thyroid Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: II

Urothelial Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Uterine Cancer

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Canton

Phase: II

Texas Oncology-Canton

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Canton

Title: PI/II Cholangiocarcinoma CX-4945 w Gem View

Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)

Indication: Biliary Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph2 SC Pertuz+Trastuz HER2+ BC View

Description: A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2- POSITIVE EARLY BREAST CANCER (MO40628)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Canton

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Canton

Phase: III

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: I

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/2 AGEN1884 Adv Refractory cancer View

Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III/IV

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II/III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph1b/2 R/R FL, R/R DLBCL View

Description: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: I

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: III

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: I

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: II

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: I

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: IV

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: I

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Canton

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Canton

Phase: II

Texas Oncology-Longview Cancer Center

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Longview Cancer Center

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III/IV

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Texas Oncology-Paris

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II

Texas Oncology-Tyler

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Tyler

Title: PI/II Cholangiocarcinoma CX-4945 w Gem View

Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 SC Pertuz+Trastuz HER2+ BC View

Description: A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2- POSITIVE EARLY BREAST CANCER (MO40628)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Tyler

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 AGEN1884 Adv Refractory cancer View

Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III/IV

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 R/R FL, R/R DLBCL View

Description: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: II

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: II

No Phase

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Longview Cancer Center

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Tyler

Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View

Indication: Epithelial Carcinomas

Location: Texas Oncology-Canton

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1/2 PIM kinase Adv Malignancies View

Description: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/1b MGCD516 Solid tumors View

Description: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH TP-1287 Solid tumor View

Description: A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors (TP-1287-101)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Phase I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 AGEN1884 Adv Refractory cancer View

Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 AGEN1884 Adv Refractory cancer View

Description: A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1b/2 R/R FL, R/R DLBCL View

Description: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 R/R FL, R/R DLBCL View

Description: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO29834)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Canton

Phase: I/II

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 INCB001158 + SC Dara vs Dara SC MM View

Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Phase II

Title: PI/II Cholangiocarcinoma CX-4945 w Gem View

Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: PI/II Cholangiocarcinoma CX-4945 w Gem View

Description: A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma (S4-13-001)

Indication: Biliary Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 SC Pertuz+Trastuz HER2+ BC View

Description: A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2- POSITIVE EARLY BREAST CANCER (MO40628)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 SC Pertuz+Trastuz HER2+ BC View

Description: A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2- POSITIVE EARLY BREAST CANCER (MO40628)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Cervical Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Colon Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Esophageal Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Gastric Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Head and Neck Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Liver Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 MGCDs+Nivo NSCLC View

Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: TGR-1202 +/- Ublituximab in NHL View

Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 R/R MCL (CITADEL-205) View

Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: CheckMate 848: Ph2 Nivo+Ipi Solid tumors View

Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Indication: Uterine Cancer

Location: Texas Oncology-Canton

Phase: II

Phase II/III

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Atezo Rollover for GNE & Roche View

Description: BO39633 (IMbrella A), An open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in A Genentech- and/or F.Hoffman-La Roche Ltd. sponsored Atezolizumab Study

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: II/III

Phase III

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Pembro HR+/HER2- BC View

Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

Indication: Breast Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Hematologic

Location: Texas Oncology-Canton

Phase: III

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Leukemia

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 3 Sit+Nivo vs. Docetaxel NSCLC View

Description: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Rituximab +/- Ibrutinib tx-naive FL View

Description: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton''s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 R/R CLL/SLL View

Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)

Indication: Lymphomas

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HR MDS, CMML, AML View

Description: Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Ovarian Cancer

Location: Texas Oncology-Canton

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 TSR-042, Niraparib Ovarian FIRST View

Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Indication: Peritoneal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Canton

Phase: III

Phase III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase: III/IV

Phase IV

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph4 Ixazomib+Lena & Dex MM (MM-6) View

Description: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

Indication: Myelomas

Location: Texas Oncology-Canton

Phase: IV